Active, not recruitingPhase 2NCT04209660

Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers

Studying Adenoid cystic carcinoma of the cervix uteri

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Memorial Sloan Kettering Cancer Center
Principal Investigator
Alan Ho, MD, PhD
Memorial Sloan Kettering Cancer Center
Intervention
Lenvatinib(drug)
Enrollment
64 enrolled
Eligibility
18 years · All sexes
Timeline
20202026

Study locations (8)

Collaborators

Merck Sharp & Dohme LLC · Eisai Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04209660 on ClinicalTrials.gov

Other trials for Adenoid cystic carcinoma of the cervix uteri

Additional recruiting or active studies for the same condition.

See all trials for Adenoid cystic carcinoma of the cervix uteri

← Back to all trials